Year: 2024
Type: dissertation
Abstract: Osteoarthritis (OA) is a common degenerative joint disease, a major cause of disability glob- ally, whose economic burden is substantial, thus requiring effective treatments to reduce its burden and improve patients’ quality of life. In this context, the main strategy here followed was the use of Low Transition Temperature Mixtures (LTTMs) to incorporate drugs and biopol- ymer(s) already prescribed in OA therapeutics (e.g.: non-steroidal anti-inflammatory drugs (NSAIDs) and hyaluronic acid (HA), the main component of joints lubricant - synovial fluid), in such a way that it can improve their efficiency, overcome their limitations, and reduce the ap- proval-time needed to reach the market. LTTMs are particularly promising to enhance drugs' bioavailability and to be used as con- trolled delivery systems, especially upon combination with biomaterials, such as polymers. Hence, the main scope of this thesis was to provide an innovative therapeutic approach com- bining the following features: i. LTTM constituents with beneficial properties for OA therapy. Different LTTM compositions were designed, developed, and characterized envisioning added synergetic action in OA ther- apy. ii. Increased NSAIDs bioavailability. Selected LTTMs were studied to identify the most prom- ising LTTM+NSAID combinations concerning this feature. iii. Compatibility towards the inclusion of selected biopolymers. An injectable formulation was designed and characterized envisioning the inclusion of selected biopolymers in the same LTTM media used to enhance the bioavailability of NSAIDs. iv. Viability for intra-articular administration. The designed formulation was studied aiming to validate proper features for the intended application. v. In vivo therapeutic potential for OA. The developed injectable was evaluated in a post- traumatic OA rat model. Briefly, glycerol:sorbitol (GS) emerged as a promising lubricant LTTM, improved celecoxib’s (CEX) solubility and was compatible with HA, rendering an alternative to conventional physio- logic solutions. GS+HA combination yielded a stable, injectable gel mimicking synovial fluid properties, further enhanced CEX bioavailability and modulated its release kinetics. In vivo, the HA+GS+CEX formulation effectively reduced pain and inflammation while distinctively inhibit- ing cartilage and bone degradation, contrarily to HA or HA+CEX alone. Overall, this work allowed to develop a product prototype assembling two therapeutic agents individually approved for OA therapy in a unique formulation with improved therapeu- tic potential and convenience (2-in-1). An injectable formulation with the accomplished fea- tures is not yet available in the market and such a product is of high social and economic interest.
Author: Roda, Ana Sofia Martins
Institution: Universidade Nova de Lisboa
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7046990945
